...
首页> 外文期刊>Transplantation Proceedings >Human Immune Reconstitution With Spleen Cells in SCID/Beige Mice.
【24h】

Human Immune Reconstitution With Spleen Cells in SCID/Beige Mice.

机译:SCID /米色小鼠脾脏细胞的人体免疫重建。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: We developed an original experimental model to study chronic vascular rejection (CVR) consisting of a graft of human mesenteric artery followed by human immune reconstitution into CB.17 SCID/Beige mice. Human immune reconstitution achieved after human PBMC injection has often been variable and incomplete. The aim of this work was to develop an alternative method to achieve a complete, functional human immune reconstitution. METHOD: After institutional authorizations, spleen cells were recovered from cadaveric organ donors. Single intraperitoneal injections of various doses of spleen cells were made into 70 CB.17 SCID/Beige mice. Reconstitution of the human immune system was monitored by flow cytometry (circulating human cells) and ELISA (human IgG). Colonization of murine lymphoid organs by human cells was studied by immunohistochemistry and flow cytometry. Evaluation of the immune function consisted of examination of CVR lesions in human arterial grafts. The animals were humanely killed atday 28. RESULTS: After injection of 30 to 40 x 10(6) spleen cells, the mice showed significant human CD3(+), CD19(+), and CD56(+) populations in peripheral blood. The mean human cells levels were, respectively, 8.2% +/- 5.4%, 2.9% +/- 1.2%, and 5.3% +/- 5.1%. Murine spleen and mesenteric lymph nodes were colonized by human T and B cells, while the murine thymus was only colonized by human T cells. Human IgG was detected in murine serum (65.9 +/- 63.3 mg/L) and typical CVR lesions were observed within the allogeneic grafts. CONCLUSION: Intraperitoneal injection of 30 to 40 x 10(6) human spleen cells into CB.17 SCID/Beige mice induces complete and functional human immune reconstitution allowing the study of CVR under human allogeneic conditions.
机译:背景:我们开发了一个原始的实验模型来研究慢性血管排斥(CVR),该血管由人类肠系膜动脉移植物,然后将人类免疫重建为CB.17 SCID /米色小鼠组成。注射人PBMC后实现的人体免疫重建通常是可变且不完整的。这项工作的目的是开发一种替代方法,以实现完整的功能性人体免疫重建。方法:在机构授权后,从尸体器官供体中回收脾细胞。将70只CB.17 SCID / Beige小鼠单次腹膜内注射各种剂量的脾细胞。通过流式细胞仪(循环人细胞)和ELISA(人IgG)监测人免疫系统的重建。通过免疫组织化学和流式细胞仪研究了人类细胞对鼠类淋巴器官的定殖。免疫功能的评估包括检查人动脉移植物中的CVR病变。这些动物在第28天被人道杀死。结果:注射30至40 x 10(6)脾细胞后,小鼠在外周血中显示出明显的人类CD3(+),CD19(+)和CD56(+)种群。人细胞平均水平分别为8.2%+/- 5.4%,2.9%+/- 1.2%和5.3%+/- 5.1%。鼠脾和肠系膜淋巴结被人T和B细胞定殖,而鼠腺胸腺仅被人T细胞定殖。在鼠血清中检测到人IgG(65.9 +/- 63.3 mg / L),在同种异体移植物中观察到典型的CVR病变。结论:将腹膜内注射30至40 x 10(6)人脾细胞到CB.17 SCID /米色小鼠中可诱导出完整的功能性人免疫重建,从而可以在人同种异体条件下研究CVR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号